CROMSOURCE
, an international full service contract research organization (CRO) today announced the completion and opening of a new office building in Warsaw, Poland and the movement of key company services to this location.
‘Poland has been a key location for CROMSOURCE since our inception in 1994 ', noted Oriana Zerbini MD, Chief Executive Officer of CROMSOURCE. ‘We have a very large team in Poland which is a key country for delivery of our clinical projects. Our unique expertise in Poland and other Central and Eastern European countries provides our sponsors with the opportunity to complete their projects in a high quality, cost competitive and high enrolling environment. This is in large part due to the wide network of expert and committed investigators with whom CROMSOURCE has established a strong relationship based on mutual trust. I am delighted to announce that our long term project to continually develop our presence in Poland continues with the completed construction of our new offices in Warsaw and the relocation of our general company services there.’
Wanda Malkowska, Managing Director of CROMSOURCE sp. z o.o stated ‘In 2011 we rejected options to lease new premises and instead initiated a plan to invest in the construction of a new office building in Warsaw to accommodate our growing team in Poland. This project, which was entirely self-financed, has now been completed successfully and I can report that the move proceeded without any adverse impact on our operations or service to our clients.’
The new office is located in the Żoliborz district of Warsaw, only 4km (2.5 miles) from the city center and just 12km (7.5 miles) from Chopin airport. The office space is greater than 1000m2 (10,750 ft2) and incorporates a secure basement for archiving and storage. The building will house functions including Clinical Operations, Staffing Solutions, Human Resources Recrutiment & Selection, Accounting, Finance. This is also the location of Financial Service Center Unit that manages all invoicing, accounting and project administration activities for all Group entities following standardised procedures developed over many years.
About CROMSOURCE: CROMSOURCE is a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. CROMSOURCE was founded in 1994 and is unique in guaranteeing our clients that their trials will be delivered on time and within the contract price (our End-to-End guarantee).
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.